Merrill Lynch Greater Europe IT PLC
23 February 2007
MERRILL LYNCH GREATER EUROPE INVESTMENT TRUST plc
All information is at 31 January 2007 and unaudited.
Performance at month end with net income reinvested
One Three One Since launch
Month Months Year (20Sep04)
Net asset value 1.6% 6.7% 17.1% 79.5%
Share price 1.8% 7.0% 13.8% 72.3%
FTSE World Europe ex UK 1.0% 6.1% 17.6% 66.8%
Sources: BlackRock and Datastream.
At month end
Net asset value: 175.23p Includes net revenue of 0.11p
Share price: 168.00p
Discount to NAV: 4.1%
Gearing: 12.9%
Net yield: 1.2%
Total assets: £246.6m
Ordinary shares in issue*: 124,729,045
Benchmark
Sector Analysis Total Assets Index Country Analysis Total Assets
(%) (%) (%)
Financials 42.1 35.2 Germany 18.3
Healthcare 10.9 2.9 France 15.8
Basic Materials 8.8 5.2 Switzerland 14.8
Oil & Gas 8.4 6.9 Italy 10.4
Industrials 8.3 10.4 Spain 6.4
Utilities 5.4 9.2 Russia 6.2
Consumer Goods 4.7 11.5 Ireland 4.0
Telecommunications 4.6 7.6 Netherlands 3.4
Consumer Services 2.6 6.5 Greece 3.0
Other Investments 2.0 - Turkey 2.8
Technology 1.9 4.6 Finland 2.7
Net current assets 0.3 - Belgium 2.1
Denmark 2.0
Sweden 2.0
Norway 1.7
Israel 1.3
UK 1.1
Austria 1.0
Poland 0.7
Net current assets 0.3
----- ----- -----
100.0 100.0 100.0
----- ----- -----
Ten Largest Equity Investments
Company Country of Risk
Allianz Germany
AXA France
BBVA Spain
Credit Suisse Switzerland
Novartis Switzerland
Roche Holdings Switzerland
Societe Generale France
Telefonica Spain
UBS Switzerland
Unicredito Italy
Commenting on the markets, James Macmillan, representing the Investment Manager noted:
European equity markets continued on an upward trend in January, with the FTSE World Europe ex UK (net) returning 1.0%
in sterling terms. Investors were encouraged by evidence of a 'soft landing' for the US economy and the beneficial
impact of falling energy prices on inflation and household purchasing power. The news on economic growth in Europe was
also encouraging, particularly in Germany, and the stream of mergers & acquisitions transactions continued into the New
Year. The performance in Emerging Europe was negatively impacted by Russia which suffered from a continued decline in
the oil price. This was reflected in the MSCI Emerging Europe Index (net) return of -2.9% in sterling terms.
The Company's NAV returned 1.6% during January outperforming the reference index by 0.6%. The contribution from the
Emerging Europe region was positive due to strong stock selection in Turkey and Russia. The use of flexible gearing was
also beneficial with the Company benefiting from being positively geared in a rising market.
During the month the Company benefited from strong stock selection across a range of sectors. Within the banking sector
the Company's holdings in Kaupthing Bank, Bank of Piraeus, EFG Eurobank Ergas and Sekerbank all had a positive
contribution to performance. Elsewhere other strong performing stocks were pharmaceutical group Bayer, steel company
Arcelor Mittal, and cement producer Holcim.
The stocks which detracted from performance were mainly found in the utility sectors which fell reflecting the downward
moves in the power prices. Individual stocks included German and French power utilties RWE, E.On and EDF. Other stocks
to have a negative effect were steel pipe manufacturer Vallourec, food manufacturer Nestle and re-insurer Munich Re.
During the month the Company increased its exposure to the pharmaceutical and material sectors through the purchase of
holdings in Roche, Teva Pharma and Holcim. These transactions were funded by reducing the Company's exposure to
utilities and food beverage and tobacco through the sale of E.On and Nestle stock.
The Company continues to have a bias towards financials, through banks and diversified financials, along with
pharmaceuticals, materials and energy. Exposure to Emerging Europe increased during the month to finish at 11%. The
Company ended the month with a net market exposure of 112.9%.
We remain positive on the prospects for European equities. The latest evidence appears to suggest that the Global
economy remains in robust health with a slight tempering of growth rather than the emergence of a recession or a serious
slowdown. European companies have generally reported strong Q4 results, and profits have proved resilient to a modest
slowdown in the US, due to robust export demand from Asia and corporate restructuring. European equity valuations are
attractive, earnings growth is strong and earnings revisions remain positive.
Latest Latest information is available by typing www.blackrock.co.uk/its on the internet, 'BLRKINDEX' on Reuters, 'BLRK'
on Bloomberg or '8800' on Topic 3 (ICV terminal).
23 February 2007
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.